Antiretroviral therapy is a medication which is used in the treatment of HIV. Antiretroviral therapy do not kill the virus, instead it slows down the growth of the virus and so is the HIV disease itself. HIV is continued to be one of the major public health issue globally. According to the report published by WHO in July 2019, 770 000 people have died of HIV related causes globally in the year 2018. Market players are trying to expand the therapeutic application of antiretroviral therapy thus creating more opportunity and scope for the growth of the antiretroviral therapy market in the future.
Rising prevalence rate of HIV is one of the major factors driving growth of the antiretroviral therapy market. Also, increasing adoption of antiretroviral therapy coverage rate and availability of the antiretroviral therapy medication is another factors surging the growth of the antiretroviral therapy market. The increasing research and development activities for developing better therapy for HIV is aiding in growth of the antiretroviral therapy market. Moreover, decreased cost of treatment and improved diagnosis rate is anticipated to boost the growth of the antiretroviral therapy market. Growing awareness of people for early treatment of the HIV or AIDS is further supporting the antiretroviral therapy market. New drug launches and products in pipeline for HIV treatment is further expected to drive growth of the antiretroviral therapy. Furthermore, favorable steps taken by government and NGOs to provide treatment for diseases like HIV is boosting the growth of the antiretroviral therapy. However, there are several side effects associated with the therapy thus hampering the growth of the antiretroviral therapy market.
The antiretroviral therapy market is segmented on the basis of application, route of administration and distribution channel.
Based on drug class, the antiretroviral therapy market is segmented into
Based on route of administration, the antiretroviral therapy market is segmented into
Based on distribution channel, the antiretroviral therapy market is segmented into
Antiretroviral therapy drug market is expected to have robust growth over the forecast period. Among the drug class segment, multi-class drugs combination segment is expected to dominate the antiretroviral therapy market as it provides more efficient treatment for HIV. By route of administration the antiretroviral therapy market is classified into oral and intravenous. The oral segment is expected to dominate the antiretroviral therapy market as there are several side-effects associated with the intravenous injections. By distribution channel type, retail pharmacy is expected to dominate the market owing to higher patient footfall.
The North America is accounted for significant market share in terms of revenue and is expected to dominate the antiretroviral therapy market over the forecast period. This is attributed to the rising HIV patients and presence of market players in the region. Also, intensive research and development activities is further aiding in the growth of the antiretroviral therapy market. Europe is accounted for second most lucrative region due to higher adoption of antiretroviral therapy medication. Also improved healthcare facilities and FDA approval of several antiretroviral therapy medicines in the region is further expected to drive the growth of the antiretroviral therapy market in the region. The Asia Pacific is expected to register prominent growth in the near future, owing to the increasing HIV patients and rising awareness of people towards HIV care and procedures in the region. The higher disposable income of the people and increasing healthcare per capita is also contributing to the antiretroviral therapy market growth.
The major key players operating in the antiretroviral therapy market are Cipla Inc., ViiV Healthcare, Gilead Sciences, Inc., GlaxoSmithKline Plc., Bristol-Myers Squibb Company, C.H. Boehringer Sohn AG & Ko. KG, Janssen Pharmaceuticals, Inc. (Johnson and Johnson), AbbVie Inc.(Abott Laboratories), Sun Pharmaceuticals Industries Ltd., and Merck & co.
The report covers exhaustive analysis on:
Regional analysis includes